The stock price of Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) has plunged by -2.81 when compared to previous closing price of 64.84, but the company has seen a -4.77% decline in its stock price over the last five trading sessions. investors.com reported 2025-05-29 that Rhythm stock is approaching its all-time high in a long base. Rhythm makes drugs to treat disorders due to genetic changes.
Is It Worth Investing in Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Right Now?
Moreover, the 36-month beta value for RYTM is 2.30. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RYTM is 58.22M and currently, short sellers hold a 8.20% of that float. On June 13, 2025, RYTM’s average trading volume was 707.98K shares.
RYTM’s Market Performance
RYTM stock saw an increase of -4.77% in the past week, with a monthly gain of 10.97% and a quarterly increase of 25.44%. The volatility ratio for the week is 2.07%, and the volatility levels for the last 30 days are 2.92% for Rhythm Pharmaceuticals Inc (RYTM). The simple moving average for the past 20 days is -0.28% for RYTM’s stock, with a 12.31% simple moving average for the past 200 days.
Analysts’ Opinion of RYTM
Many brokerage firms have already submitted their reports for RYTM stocks, with BofA Securities repeating the rating for RYTM by listing it as a “Buy.” The predicted price for RYTM in the upcoming period, according to BofA Securities is $63 based on the research report published on April 07, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see RYTM reach a price target of $78. The rating they have provided for RYTM stocks is “Buy” according to the report published on March 05th, 2025.
Jefferies gave a rating of “Buy” to RYTM, setting the target price at $80 in the report published on January 02nd of the current year.
RYTM Trading at 2.97% from the 50-Day Moving Average
After a stumble in the market that brought RYTM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.83% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RYTM starting from German Christopher Paul, who sale 2,069 shares at the price of $67.19 back on Jun 10 ’25. After this action, German Christopher Paul now owns 1,889 shares of Rhythm Pharmaceuticals Inc, valued at $139,016 using the latest closing price.
Cramer Pamela J., the Chief Human Resources Officer of Rhythm Pharmaceuticals Inc, sale 7,031 shares at $68.05 during a trade that took place back on Jun 06 ’25, which means that Cramer Pamela J. is holding 19,209 shares at $478,435 based on the most recent closing price.
Stock Fundamentals for RYTM
Current profitability levels for the company are sitting at:
- -1.26 for the present operating margin
- 0.89 for the gross margin
The net margin for Rhythm Pharmaceuticals Inc stands at -1.24. The total capital return value is set at -0.63. Equity return is now at value -418.97, with -52.28 for asset returns.
Based on Rhythm Pharmaceuticals Inc (RYTM), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -27.93. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -8.34.
Currently, EBITDA for the company is -238.09 million with net debt to EBITDA at 0.68. When we switch over and look at the enterprise to sales, we see a ratio of 28.55. The receivables turnover for the company is 7.68for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.30.
Conclusion
To wrap up, the performance of Rhythm Pharmaceuticals Inc (RYTM) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
